Head-to-head · WeighScore
Bionomy Health vs Zealthy
The verdict
Bionomy Health takes it — 73.6/100 to 46.7/100.
Bionomy Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bionomy Health is a physician-led, direct-to-consumer men's telehealth brand offering compounded GLP-1 weight-loss medication alongside testosterone, peptides, and longevity protocols.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bionomy Health | Zealthy |
|---|---|---|
| WeighScore | 73.6/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #71 | #496 |
| Semaglutide | $189/mo | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $249/mo | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 48 states | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #71 · C
Strengths
- Offers both compounded semaglutide (189/mo) and tirzepatide (249/mo) with pay-per-prescription pricing and no subscription
- Physician-led with a free, physician-reviewed intake before you pay anything
- Fills through LegitScript-certified compounding pharmacies Strive and Absolute; available in 48 states
- Pairs GLP-1 protocols with muscle-preserve supplements and a written training note to protect lean mass
Where it loses points
- Men's health brand, so the site framing and protocols are geared to men rather than a general audience
- New brand launched in 2026 with limited independent reviews and track record
- Not available in Alaska or Hawaii; compounded medications are not FDA-approved
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.